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Introduction
Haloperidol, a first generation antipsychotic, is used in the treatment of schizophrenia, tics in Tourette's syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis and hallucinations in alcohol withdrawal [1] . Haloperidol functions as a high affinity dopamine D2 receptor (D2R) antagonist [2] , but it also increases expression of type 1 IP 3 receptors (IP 3 R1) and sigma 1 receptors [3, 4, 5] . Up to now, mechanism of haloperidol action through these three receptor types and/or their mutual communication is not clear.
Dopamine and its signaling through D2R, which signals via inhibitory Gi/o proteins and inhibits the production of cAMP, has been described in many neurological diseases, e.g. schizophrenia [6, 7] . However, putative D1R/D2R heterodimers have been suggested to regulate diacylglycerol and IP 3 signaling by activating Gq [8] . One important aspect of the D1R/D2R heterodimer's signaling in cells is requirement to co-activate both D1 and D2 receptor moiety to activate Gq. Physiological relevance of such complex was described in several papers. Recently we have shown, that in differentiated neuronal NG-108 cells, disruption of D1R/D2R complex due to the haloperidol treatment might affect neuronal plasticity [9] . Use of the fluorescence resonance energy transfer technology indicated that low concentration of clozapine that is sufficient to saturate the high affinity site, uncoupled the D1R/D2R heterodimers [10] . Changes in the ratio of the D1R:D2R could contribute to cocaine-induced behavioral plasticity and demonstrates a role of G protein coupled receptor associated sorting protein-1 in regulating both the levels of the D2R and cocaine sensitization [11] . Activation of the D1R/D2R heteromer in medium spiny neurons resulted in the simultaneous, but differential regulation of proteins involved in GABA and glutamate production or vesicular uptake in the nucleus accumbens, ventral tegmental area, caudate putamen and substantia nigra [12] . On the other hand, based on their experiments Frederick and co-workers [13] proposed that D1R/D2R heteromers do not play significant role in the normal adults' brain. In cardiovascular system, potential adverse effect of the haloperidol includes an abnormally prolonged corrected QT (QTc) interval and an increased risk of developing torsade de pointes, a type of tachyarrhythmia associated with sudden death [14] [15] [16] . In guinea pig heart, haloperidol has a significant effect on heart rate and QTc interval duration [5] . This effect might be realized partly through modulation of potassium currents, partly through an increase in the gene expression of sigma 1 receptors and IP 3 receptors. Changes in the expression of these receptors may lead to altered calcium handling in cardiomyocytes and thus contribute to changed sensitivity of cardiac cell to arrhythmias. Nevertheless, precise role of dopamine receptors has not been evaluated yet.
Based on the current knowledge we hypothesize that D1R/D2R complex might serve as the interconnection in the haloperidol effect on IP 3 R1 and thus on sigma 1 receptors. Therefore, we used a selective blocker of D2Rs -melperone -to evaluate a role of these receptors in the haloperidol-induced increase in IP 3 R1 and sigma 1 receptors and to compare the physiological effect of melperone and haloperidol on the basic heart parameters in rats.
Material and methods

Cell cultures
The neuroblastoma-glioma cell line NG-108 (PAA Laboratories, Germany, provided by Dr. Lacinova) and cardiac H9c2 cell line were used in these experiments. Both cell lines were incubated in DMEM with 4.5 g glucose/l and 110 mg sodium pyruvate/l and L-glutamine (Sigma Life Sciences) supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin mixture. NG-108 cells were cultivated and differentiated with dibutyryl cAMP (dbcAMP; Sigma-Aldrich, USA) in 2% FBS as described in Kubickova et al. [17] .
Unless stated otherwise, cells were treated with the prototypical sigma 1 receptor ligand haloperidol (Hal; 10 μM; Sigma Aldrich, USA) or the specific D2Rs antagonist Melperone hydrochloride (Me; 150 nM; Tocris Bioscience UK), D2 agonist Sumanirole maleate (Sum, 150 nM, Tocris Bioscience, UK) or D1 agonist SKF -38393 (SK, 10 μM, SigmaAldrich, USA).
Animal experiments
Animal experiments were carried out according to the recommendations of European Community Guide for the Care and Use of Laboratory Animals and according to the experimental protocol approved by the Committee for Ensuring the Welfare of Laboratory Animals at Masaryk University, Faculty of Medicine.
The study was performed on 24 Wistar albino rats (male only, 271.5 ± 6.5 g), 3 month old. Animals were housed in the environment with monitored atmospheric pressure, humidity, room temperature, and light cycle 12/12 light/dark. Animals were randomly divided into three groups: control (cont; n = 8; average body mass 274.8 ± 11.6 g), haloperidol-treated (Hal; n = 8; average body mass 268.1 ± 13.3 g) and melperone-treated (Me; n = 8; average body mass 271.5 ± 9.9 g). According to the experimental group, one of the following substances was administered by intraperitoneal injection once a day for 21 consecutive days: vehicle (2% ethanol in aqua pro injection) in volume of 13.3 ml/kg of actual body mass, Hal (Sigma Aldrich, USA) in the dose of 2 mg/kg or Me (Tocris Bioscience, UK) in the dose of 2 mg/kg. Drugs and/or vehicle were administered in the same daytime (around 13:00). Measurements were performed before dose application (between approx. 10:00 and 13:00). Gentle handling and quiet approach was applied to reduce discomfort of animals during daily manipulation.
At the day 22 (24 h after the last dose), animals were deeply anesthetized (Ketamin, Xylasine) and then sacrificed. Samples from the left ventricle were collected. Samples were then stabilized and stored for further analysis. Samples for gene expression were frozen in liquid nitrogen and then stored at −80°C.
2.3. RNA isolation, cDNA preparation, PCR and real-time PCR Total RNA was isolated by the TRI Reagent (MRC Ltd., Cincinnati, OH, USA) as described in Markova et al. [15] . Reverse transcription was performed using 1.5 μg of total RNA and Ready-To-Go You-Prime FirstStrand Beads (GE Healthcare Life Sciences, Germany) with the pd. (N6) primer. PCR specific for cDNA of a rat sigma 1 receptor (GI 38541100) and IP 3 R1 (GI 13752805) was performed as described in Novakova et al. [4] . Following primers for rat D1R (GI 752293509), D2R (GI 203905) and cyclophylin A (GI 203701); as a housekeeping gene control for the semi-quantitative evaluation of PCR) were used: D1R forward: 5′-ATC TCT TGG TGG CTG TCC TGG-3′, D1R reverse: 5′-GGG GGT CAT CTT CCT CTC ATA C-3′; D2R forward: 5′-CCT TCC TTG ACC TTC CTC TT-3′, D2R reverse: 5′-CCC TGC TTT CCT ATG TGG TTC-3′; CYCLO1 5′-CGT GCT CTG AGC ACT GGG GAG AAA-3′ and CYCLO2 5′-CAT GCC TTC TTT CAC CTT CCC AAA GAC-3′. For the relative quantification by real-time PCR, we used identical primers and cDNA template. Real-time PCR amplifications were carried out as described in Markova et al. [18] using the SYBR Green Master Mix with ROX reference dye (Life Sciences, EU).
Immunofluorescence
Cells grown on glass coverslips were fixed in ice-cold methanol. Non-specific binding was blocked by incubation with PBS containing 3% bovine serum albumin (BSA) for 60 min at a room temperature. The cells were then incubated with primary antibodies diluted PBS with 1% BSA (PBS-BSA) for 1 h at 37°C. Following antibodies and corresponding dilutions were used: rabbit polyclonal antibody anti-OPRS1 (ab53852, Abcam, USA; dilution 1:200) directed against a synthetic peptide derived from the C-terminal region of rat sigma 1 peptide; mouse monoclonal [SG2-D1a] to dopamine receptor D1 (ab78021, Abcam, USA, dilution 1:250), raised against recombinant rat dopamine receptor D1 carboxy terminus; rabbit polyclonal anti-dopamine D2 receptor antibody (ab21218; Abcam, USA; 1:400) and mouse anti-IP 3 R1 monoclonal antibody (407143, Calbiochem; 1:100). Afterwards, the cells were washed three times with PBS-BSA for 10 min, incubated with CF Fluor® 488 or CF Fluor® 594 goat anti-rabbit (or anti-mouse) IgG diluted 1:1000 in PBS-BSA for 1 h at 37°C, and washed as described previously. Finally, the coverslips were mounted onto slides in mounting medium Fluoroshield with DAPI (F6057, Sigma). Images of all samples were acquired with the same microscope setup. Cells were visualized by epifluorescence microscopy using Nikon Eclipse Ti-S/L100 (Nikon, Japan); NIS elements software (Nikon, Japan) was used to process images and to evaluate the resultant pictures.
Western blot analysis
Protein concentration of the lysate was determined by using the method of Lowry et al. [19] . Whole procedure is described in detail in Lencesova et al. [20] . An enhanced chemiluminescence detection system (LuminataTM Crescendo Western HRP Substrate, Millipore) was used to detect the bound antibodies. To detect D1R protein, we used a rabbit monoclonal anti-dopamine D1 receptor antibody (ab81296, Abcam, UK) and to detect D2R protein, we used a rabbit polyclonal anti-dopamine D2 receptor antibody (ab21218, Abcam, UK). As a housekeeper, we used β-actin mouse monoclonal antibody (ab6276, Abcam, UK).
Proximity ligation assay (PLA)
The proximity ligation assay (PLA) was used for in situ detection of the interaction between D1R and D2R receptors. The assay was performed in a humidified chamber at 37°C according to the manufacturer's instructions (Olink Bioscience, Sweden). H9c2 cells were seeded on glass coverslips and allowed to attach prior the exposure to 10 μM haloperidol. After 24 h of haloperidol treatment, the cells were fixed with methanol, blocked with Blocking solution for 30 min, incubated with a mixture of specific primary antibodies against D1R and D2R for 1 h, washed three times, and incubated with plus and minus PLA probes for 1 h. Then, the cells were washed (3 × 5 min), incubated for 40 min with ligation mixture containing connector oligonucleotides, washed again, and incubated with amplification mixture containing fluorescently labeled DNA probe for 100 min. After a final wash, the samples were mounted and the signal representing interaction between D1R and D2R was analyzed using fluorescent or confocal microscope. For this method, following antibodies were used: mouse monoclonal antibody to dopamine receptor D1 [SG2-D1α] (ab78021, Abcam, UK) and rabbit polyclonal antibody to dopamine receptor D2 (ab21218, Abcam, UK). Interactions between D1R and D2R were visualized by epifluorescence microscopy using Nikon Eclipse Ti-S/L100 (Nikon, Japan) equipped with corresponding set of excitation/emission filters. NIS elements software (Nikon, Japan) was used to process images and to evaluate the resultant pictures. Results were verified on confocal microscope imaging system TCS SPE-II (Leica, Wetzlar, Germany) with 405-nm and 532-nm lasers for excitation. To measure the intensity of fluorescence, software -LAS AF (Leica Application Software platform for confocal microscope) was used.
Immunoprecipitation
Immunoprecipitation was performed as described in Markova et al. [18] . Briefly, the appropriate polyclonal antibody was incubated with 60 μl of washed magnetic beads (Dynabeads 280 coated with sheep anti-rabbit IgG Life Technologies, Dynal AS, Norway) overnight at 4°C on a rotator (VWR International, LLC, PA, USA). The beads with attached antibodies were washed twice (200 μl) with PBS-BSA. Proteins were immunoprecipitated from 500 μg of detergent-extracted total protein via their incubation with antibody-bound beads for 3 h at 4°C. Bead complexes were washed with PTA (4-times with 200 μl; 145 mM NaCl, 10 mM NaH 2 PO 4 , 10 mM sodium azide, and 0.5% Tween 20; pH 7.0). Immunoprecipitated proteins were then extracted with 60 μl of 2× Laemmli loading buffer according to the manufacturer's instructions (Bio-Rad) and boiled for 5 min. The following antibodies were used for immunoprecipitation: rabbit monoclonal [EP 1560Y] to dopamine receptor D1 (ab81296) and rabbit polyclonal antibody to dopamine D2 receptor (ab21218, Abcam, UK). The D1R antibody detects band with Mw 49 kDa and D2R antibody detects band with 50 kDa.
ECG recording and blood pressure measurement
During the whole experiment, ECG and blood pressure were recorded by non-invasive approach before the first dose of substances (day 0), then at day 4, 8, 11, 15, and 18 of administration, and finally one day after the last dose (day 22). The measurements were performed always at the same daytime (morning) and before the administration of daily dose. The non-invasive blood pressure measurement was performed on CODA 8 (Kent Scientific Corporation, USA). Five measuring cycles were performed. The value of systolic and diastolic pressure was defined as a mean calculated from valid measuring cycles in each measurement. For ECG recording, ecgTUNNEL (Emka Technologies, France) was used. At least 1 min lasting ECG record was recorded in 3 limb leads for each animal and then analyzed offline. Analysis was performed on ecgAUTO software (v3.3.3.10, Emca Technologies, France). Heart rate and QT interval duration were assessed from approx. 100 detectable beats. Periods with motion artifacts were excluded from analysis. For elimination of the impact of heart rate changes on QT duration, QT interval was corrected according to Framingham formula: QTcFra = QT − 0.154 × (1000 − RR), where QTcFra, QT and RR are expressed in ms.
Statistical analysis
Each value represents an average of 3-9 wells from at least two independent cultivations of H9c2 and NG-108 cells. The results are presented as the mean ± S.E.M. Significant differences between the groups were determined by one-way ANOVA. For multiple comparisons, an adjusted t-test with p values corrected by the Bonferroni method was used. For animal experiments, statistics was calculated by Mann-Whitney test.
Results
Gene expression of the sigma 1 receptors (Sig1R) was significantly increased after D2R antagonist melperone (Me; 150 nM) treatment for 24 h in H9c2 and also in differentiated NG-108 cells (Fig. 1A) . Increase in Sig1R mRNA due to the melperone (Me; 150 nM) treatment was similar to that observed by haloperidol (Hal; 10 μM) in both types of cells. Sumanirol (Sum; a D2R agonist) did not change expression of the Sig1R (Fig. 1A) compared to control, untreaed cells. Combination of Sum and SK resulted in decrease of Sig1R compared to control group (Fig. 1A. ) Immunofluorescence also revealed similar signal intensity of Sig1R in Me and Hal treated group of H9c2 cells (Fig. 1B) , which was significantly higher than in control group. Sum and Sum/Hal treated group revealed much lower signal of Sig1R compared to control (Fig. 1B) . Gene expression of the IP 3 R1 was also increased in both, Me and Hal treated H9C2 and NG-108 cells (Fig. 2A) . Sum did not change expression of the IP 3 R1 compared to control, untreated group of H9c2 cells, but combination of Sum and SK decreased the expression of IP3R1 compared to control group ( Fig. 2A) . Increased expression of the IP 3 R1 was verified also by immunofluorescence, where increased IP 3 R1 signal was visible after Me and Hal treatment (Fig. 2B) , compared to controls. Me increased gene expression of the D2Rs, probably as a consequence of its decreased activity ( Fig. 3A;B) , similarly to Hal. Interestingly, Me has the same effect on gene expression of D1Rs as Hal, since both, Me and Hal significantly decreased expression of D1Rs (Fig. 3A) . This observation was confirmed by immunofluorescence using D2R and D1R primary antibodies (Fig. 3C ) and also by Western blot analysis (Fig. 3D) . Dual labeling of D1R (red) and D2R (green) displayed yellowish colour in controls (Fig. 4A ), but not in Hal treated cells, where a strong green signal of D2R was detectable and only a weak signal of D1R occurred. Immunoprecipitation with immunoprecipitated D2R qualitatively determined existence of D1R/D2R heterocomplex in control, Me and Hal treated groups (Fig. 4B, left) . To verify the result with D2R immunoprecipitation, reverse immunoprecipitation with precipitated D1R was performed as well (Fig.4B, right) . Proximity ligation assay (PLA) revealed a D1R/D2R heterodimeric complex in control, but it was significantly lower in Hal and/or Me treated cells (Fig. 5) . PLA signal was also quantified and revealed much lower intensity in Hal treated group compared to control group (Fig. 5, graph) .
In rats, both systolic (SBP) and diastolic (DBP) blood pressure did not show any changes among all groups during the first week of drug administration. After one week of application, clear trend of blood pressure decrease was observed in Hal treated group (on contrary to Me group). Differences in both, SBP as well as DBP became significant after two weeks of application (haloperidol vs. melperone, p = 0.05; 6A;B). Before the drugs administration, no significant changes in heart rate among groups were found (457.1 ± 14.8 ms, 470.4 ± 8.1 ms and 468.2 ± 13.8 ms for Hal, Me and cont, respectively). No significant changes at the end of experiment were detected in group Me and cont. In group Hal, increasing heart rate was observed after 10 days of application. This increase became significant in day 18 and 22, respectively (525.6 ± 8.0 ms in day 18 and 511.0 ± 9.3 ms in day 22, respectively; p < 0.05; Fig. 6C ). No significant changes in corrected QT interval were observed among groups (not shown). In the left ventricles of these rats, D2R mRNA was increased and D1R mRNA was decreased in Me and Hal treated group compared to control, untreated group of rats (Fig. 6D) . 
Discussion
Haloperidol is a first generation of antipsychotic agent, functioning both as D2R antagonist and also as sigma1R antagonist. Growing understanding of a complex array of dopamine receptor signaling events has led to the focus on the abnormalities in intracellular signaling mechanisms as a potential cause or a modifier of pathological processes that lead to dopamine-related disorders [21] . We have clearly shown that both, sigma1 receptors and also type1 IP 3 Rs are upregulated due to haloperidol treatment in cardiomyocytes and also in neuroblastoma cell line NG-108, they form complex and also they translocate to the nuclei [3, 4] . Nevertheless, role of the D2Rs in this process is not fully elucidated yet. The D2R selective compounds represent unique pharmacological tools that have potential for use in studies on the relative contribution of the D2Rs in physiological and behavioral situations, where D2R involvement is indicated [22] . Therefore, we compared the effect of selective D2R antagonist -melperone -on the expression of Sig1Rs and IP 3 R1 due to the haloperidol treatment in H9c2 cells. Using real time PCR and immunofluorescence we observed increased expression of both these receptors due to melperone treatment and this increase was similar to that observed by haloperidol. Sumanirol -D2R agonist -did not increase expression of Sig1R or IP 3 R1. Effect of melperone on the elevation of Sig1Rs and IP 3 R1 strongly suggests involvement of D2R signaling. Also, it is obvious that the effect of haloperidol on Sig1Rs and IP 3 R1 is realized -at least partially -through the D2Rs. Question remains, what is the mechanism involved in this process. D2Rs functions have typically been associated with the regulation of cAMP and PKA via G protein-mediated signaling; particularly they are coupled to Gi/o and negatively regulate the production of cAMP, resulting in a decrease in PKA activity (for review see [23] ). Nevertheless, signaling through the phospholipase C and subsequent production of IP 3 was described, when these receptors forms heterodimers with D1Rs. Therefore, we checked expression of the D1Rs and we observed downregulation of these receptors in H9c2 cells due to haloperidol treatment. Also, proximity ligation assay showed a signal of D1R/D2R heterodimers in control, untreated cells, but not in haloperidol treated cells. Interestingly, treatment of H9c2 cells with D2 agonist sumanirol and D1 agonist SKF-38393 hydrochloride resulted in decreased expression of both IP 3 R1 and Sig1R. These results might suggest that there is enough D1R in untreated cells to form heterodimers with D2R and activate signaling through Gq and PLC, as it was verified by dual labeling. Under this arrangement, enough IP 3 is formed and IP 3 R1 could be activated. When cells are treated with haloperidol, D1Rs are markedly reduced, which will prevent formation of D1R/D2R heterodimers, subsequent production of IP 3 and activation of IP 3 R1. Impaired signaling through the IP 3 R1 will induce up-regulation in their gene expression. This observation is in line with our previous studies on differentiated NG-108 cells [9] and also with the assumption of Kaneko and co-workers [24] , who suggested that haloperidol might affect not only the adenylate cyclase system, but also the phosphoinositide response in the striatum. Moreover, physiological importance of D1R/D2R disruption was described by Perreault et al. [25] , who have shown a role of the D1R/D2R heteromer in exerting tonic inhibition on brain reward mechanisms and thus function as a brake to constrain the development and expression of addiction-like behaviors. Thompson et al. [26] have shown that in orbitofrontal cortex, targeting the putative D1R-D2R complex with a biased agonist, SKF83959, not only enhanced excitatory synaptic transmission in a PLC-dependent manner, but also improved the performance of juvenile rats on a reversal-learning task. On the other hand, Frederick et al. [13] published that in the shell of nucleus accumbens, even in neurons in which D1 and D2 receptor promoters are both active, the receptor proteins are segregated and do not form complexes.
In H9c2 cells very similar responses to Hal and Me treatment were observed. Both these compounds increased expression of the Sig1Rs, IP 3 R1, D2R and decreased expression of D1R. In order to evaluate the impact of these expression changes, selected cardiovascular parameters . In a control group, both red (A, cont D1R) and green (A, cont D2R) signal was detectable giving yellowish signal (A, cont merged), while in haloperidol (Hal) treated cells, red signal of D1R was very weak (A, Hal D1R) and only strong green signal was determined (A, Hal merged). By immunoprecipitation (B), immunoprecipitate was generated and probed with anti-D2R antibody and co-precipitated with D1R antibody (D2R/D1R). Strong signal of co-precipitation occurred in control group, but weaker signal was visible also in Me and Hal treated group. As a control, immunoprecipitated D2Rs were visualized using D2R antibody (D2R/D2R). For reverse immunoprecipitation, immunoprecipitate was generated and probed with anti-D1R antibody and coprecipitated with D2R antibody (D1R/D2R). As a control, immunoprecipitated D1Rs were visualized using D1R antibody (D1R/D1R). NC -negative control, where D1R or D2R antibodies were omitted. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) in male Wistar rats were followed. Both, SBP and DBP values were significantly decreasing in group Hal. This finding is in agreement with previously published studies reporting hypotension both in various animal models and in patients [27] [28] [29] [30] [31] [32] . Mean HR values were significantly increased from day 18 in Hal group. In previous animal studies, rather inconsistent results were reported -from no effect of haloperidol on HR to significant decrease of HR after haloperidol administration [5, [33] [34] .
However, comparison of these results with effect reported in this study is rather difficult due to different animal models used (isolated rat heart or anesthetized dogs vs. conscious rats). Moreover in most of the previous studies, only acute effects of haloperidol on HR were followed. In schizophrenic patients treated with haloperidol, significant decrease of HR was reported [30] . However, cardiac autonomic dysfunction as well as impairment of heart rate variability were repeatedly reported in patients suffering from schizophrenia (reviewed in [35, 36] ). In the present experimental setting, HR increase in haloperidol treated rats may represent a compensatory reaction balancing the decrease of arterial blood pressure.
Observed expression changes in D1R and D2R in the left ventricle of these rats are in line with previous results on H9c2 cell line. However, since changes in selected cardiovascular parameters were observed in Hal treated group and not in Me treated group we propose that D2R are not crucial in the haloperidol induced side effects on the cardiovascular system. Nevertheless, the control of cardiovascular system is very complex and a role of D2 receptor system in these processes remains to be elucidated.
Conclusion
In conclusion, we have found that in H9c2 cells, haloperidol caused disruption of D1R/D2R complex, which probably modulated signaling through the type 1 IP 3 receptors. Disruption of this complex was caused by decreased expression of D1Rs and increased D2Rs expression. D2R increase is not responsible for haloperidol-induced changes in cardiac parameters, since melperone, a specific D2R blocker, did not cause changes in heart rate and blood pressure, as was observed in haloperidol-treated group of rats.
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The authors declare that they have no conflict of interest. 5 . Formation of D1R/D2R heterodimers was detected by a proximity ligation assay. Red dots in control H9c2 cells (cont) clearly point to the formation of D1/D2 heterodimers. In haloperidol-treated group (Hal), this signal practically disappeared. NCD1-negative control, where D1R primary antibody was omitted; NCD2-negative control, where D2R primary antibody was omitted. Scale bar represents 10 μm. Quantification of the fluorescent signal per cell revealed significantly higher fluorescent intensity in control, than in haloperidol-treated group. These results are displayed as mean ± S.E.M. and n = 7. Statistical significance **p < 0.01. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Fig. 6 . Mean values of systolic and diastolic blood pressure, and also heart rate during treatment. Both, systolic blood pressure (SBP, A) and diastolic blood pressure (DBP, B) were decreased in rats at 11th day of Hal treatment and remained decreased also after 15 days of Hal treatment. Such changes were not observed in group of rats treated with Me. In these rats, heart rate (HR) was increased significantly from 18th day in rats treated with Hal, but not with Me (C). In the left ventricles of these rats we observed significant increase in D2R mRNA and decrease in D1R mRNA, as observed by PCR (D).
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